Medical Properties Trust price target lowered to $12 from $14 at Barclays

Barclays analyst Steve Valiquette lowered the firm’s price target on Medical Properties Trust to $12 from $14 and keeps an Overweight rating on the shares. Based on value-based care comps, Prospect Medical’s Prospect Health Plan could be worth $600M-$800M, which is below Medical Properties Trust’s view of "around $1B," the analyst tells investors in a research note. However, the potential price should still allow the company to recoup its $420M cost basis in Prospect’s Pennsylvania hospital real estate, contends the firm.